US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Soligenix, Inc.

2.05

-0.0618-2.93%

Volume:27.22K

Turnover:55.45K

Market Cap:6.46M

PE:-0.41

High:2.10

Open:2.04

Low:2.01

Close:2.11

Loading ...

Overview Company News Filings

Fireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc.

Zacks Small Cap Research

SNGX: Updated IIS Data Shows 75% Response Rate and Three Complete Responses…

Zacks Small Cap Research

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

SNGX: Preclinical Data Shows CiVax™ Booster Induces Broad Protection Against COVID-19…

Zacks Small Cap Research

IBN Initiates Coverage of Soligenix Inc.

BRIEF-Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Soligenix Inc reports results for the quarter ended December 31 - Earnings Summary

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

THOMSON REUTERS

Press Release: Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

Soligenix Inc expected to post a loss of 95 cents a share - Earnings Preview

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

SNGX: Presentation Highlights HyBryte Potential in CTCL…

Zacks Small Cap Research

Soligenix Inc - on Feb 5, Repays and Terminates Loan Agreement With Pontifax Medison

THOMSON REUTERS

Soligenix’s HyBryte shows efficacy in T-cell lymphoma trial

BRIEF-HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Hybryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

THOMSON REUTERS

EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year

SNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL…

Zacks Small Cap Research

Soligenix Begins Patient Enrollment for Phase 3 Study of Drug Candidate for Cutaneous T-Cell Lymphoma

MT Newswires Live

Soligenix initiates confirmatory Phase 3 trial of HyBryte

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SNGX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SNGX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNGX\",,,,,undefined,":{"symbol":"SNGX","market":"US","secType":"STK","nameCN":"Soligenix, Inc.","latestPrice":2.0482,"timestamp":1745941279415,"preClose":2.11,"halted":0,"volume":27224,"delay":0,"floatShares":3154934,"shares":3155603,"eps":-4.978626,"marketStatus":"Trading","change":-0.0618,"latestTime":"04-29 11:42:59 EDT","open":2.0398,"high":2.1,"low":2.01,"amount":55450.561913599995,"amplitude":0.042654,"askPrice":2.05,"askSize":28,"bidPrice":2,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.978626,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745956800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.11,"preHourTrading":{"tag":"盘前","latestPrice":2,"preClose":2.11,"latestTime":"09:20 EDT","volume":2173,"amount":4370.485363999999,"timestamp":1745932807996},"postHourTrading":{"tag":"盘后","latestPrice":2.07,"preClose":2.07,"latestTime":"18:51 EDT","volume":98,"amount":198.65,"timestamp":1745880702439},"volumeRatio":2.632682},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNGX\",,,,,undefined,":{"symbol":"SNGX","floatShares":3154934,"roa":"-62.88%","roe":"-248.97%","lyrEps":-4.978626,"volumeRatio":2.632682,"shares":3155603,"dividePrice":0,"high":2.1,"amplitude":0.042654,"preClose":2.11,"low":2.01,"week52Low":1.68,"pbRate":"1.57","psRate":"54.14","week52High":14.8299,"institutionHeld":0.0042,"latestPrice":2.0482,"committee":0.5625,"eps":-4.978626,"divideRate":0,"volume":27224,"delay":0,"ttmEps":-4.978626,"open":2.0398,"prevYearClose":2.695,"prevWeekClose":2.17,"prevMonthClose":2.15,"prevQuarterClose":2.15,"fiveDayClose":2.065,"twentyDayClose":2.15,"sixtyDayClose":2.33},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SNGX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530998766","title":"Fireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2530998766","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530998766?lang=en_us&edition=fundamental","pubTime":"2025-04-25 00:09","pubTimestamp":1745510940,"startTime":"0","endTime":"0","summary":"David Bautz: Hi, everyone, and welcome to the next episode of our CEO Fireside Chats. My name is David Bautz and I'm a senior biotechnology analyst here at Zacks Small Cap Research. Joining me today is Chris Schaber. He is the Chief Executive Officer of Soligenix, Inc. They are a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates two business segments. The specialized biotherapeutic segment, which is what we're going to focus on today, along with the public health solutions segment. The stock trades on the NASDAQ under the symbol SNGX. Now, the company's lead asset, HyBryte, is currently in a confirmatory phase three trial for the treatment of cutaneous T-cell lymphoma, or CTCL. The company also has two phase two trials ongoing for SGX302 for the treatment of psoriasis and SGX945 for the treatment of Behet's disease. Soligenix is a company that we have covered for a nu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fireside-chat-christopher-schaber-chief-160900353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2527115562","title":"SNGX: Updated IIS Data Shows 75% Response Rate and Three Complete Responses…","url":"https://stock-news.laohu8.com/highlight/detail?id=2527115562","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527115562?lang=en_us&edition=fundamental","pubTime":"2025-04-14 20:38","pubTimestamp":1744634280,"startTime":"0","endTime":"0","summary":"Interim Data from IIS Study Shows 75% Response Rate and Three Complete Responses. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sngx-updated-iis-data-shows-123800928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2527432159","title":"Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2527432159","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527432159?lang=en_us&edition=fundamental","pubTime":"2025-04-14 19:30","pubTimestamp":1744630200,"startTime":"0","endTime":"0","summary":"Interim Results from FDA-Funded Study Reinforces HyBryte's Rapid Response and Strong Safety Profile. \"The complete response rates observed, including three patients achieving a complete response on this study to date, as well as the consistent treatment response and safety profile across multiple HyBryte clinical studies, has been exciting to see,\" noted Dr. Kim, Principal Investigator of the IIS. \"In the first Phase 3 FLASH study, HyBryte was shown to be efficacious with a benign safety profile compared to the current therapies of steroids, chemotherapeutics and ultraviolet light in this chronic orphan disease. With limited treatment options, especially in the early stages of their disease, CTCL pat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/positive-outcome-75-ctcl-patients-113000163.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/positive-outcome-75-ctcl-patients-113000163.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4168","IDR","BK4139","SNGX"],"gpt_icon":0},{"id":"2522380305","title":"SNGX: Preclinical Data Shows CiVax™ Booster Induces Broad Protection Against COVID-19…","url":"https://stock-news.laohu8.com/highlight/detail?id=2522380305","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522380305?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:15","pubTimestamp":1742991300,"startTime":"0","endTime":"0","summary":"CiVax Booster Enhances Protection from COVID-19 in NHPs. On March 25, 2025, Soligenix, Inc.  announced a publication that includes results from a prime-boost study in non-human primates  that showed the use of CiVax, the company’s thermostabilized subunit vaccine against SARS-CoV-2, following vaccination with a primary adenovirus vaccine  resulted in a robust immune response against SARS-CoV-2 variants.The ThermoVax platform has a number of advantages over other vaccine platforms, including its use of protein subunits without the need for strict cold-storage requirements. These most recent results show that CiVax can induce a rapid, robust immune response against SARS-CoV-2 variants even when administered after another primary vaccine series. Combined with a proven vaccine technology, these results show the company’s vaccine platform could be utilized for current threats as well as those that may emerge in the future.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sngx-preclinical-data-shows-civax-121500311.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SNGX","BNTX"],"gpt_icon":0},{"id":"2522075375","title":"IBN Initiates Coverage of Soligenix Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522075375","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522075375?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:30","pubTimestamp":1742905800,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, March 25, 2025  -- via IBN – Soligenix Inc. , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with an unmet medical need, has selected IBN, a multifaceted financial news and publishing company serving private and public entities, to spearhead its corporate communications efforts.Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte  as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma . With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin  into psori","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ibn-initiates-coverage-soligenix-inc-123000018.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0823039010.USD","IBN","BK4207","BK4585","BK4535","LU0066902890.USD","IDR","LU0143863784.USD","BK4548","LU1102505762.USD","LU0181495838.USD","LU1481012133.USD","LU1102505929.USD","LU0251143458.SGD","LU1868837565.USD","SNGX","DBP","LU0531971678.HKD","BK4168","SG9999004220.SGD","LU0828237940.HKD","LU0164881194.USD","IE00B7N09G41.SGD","LU0048575426.USD","BK4139","LU0143863198.USD","IE00B0JY6M65.USD","LU0261950470.USD","LU1868838027.USD","BK4588","LU0264410563.USD","LU0823038988.USD","BK4523","LU1868837722.USD","IE00BYTNYM70.SGD"],"gpt_icon":0},{"id":"2522299180","title":"BRIEF-Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants","url":"https://stock-news.laohu8.com/highlight/detail?id=2522299180","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522299180?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:35","pubTimestamp":1742902554,"startTime":"0","endTime":"0","summary":"BRIEF-Soligenix Announces Publication Demonstrating CiVax Booster Induces Rapid Broad Protection Against COVID-19 VariantsMarch 25 (Reuters) - Soligenix Inc SNGX.O:SOLIGENIX ANNOUNCES PUBLICATION DEMO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q80B0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX"],"gpt_icon":0},{"id":"2521285354","title":"Soligenix Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2521285354","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521285354?lang=en_us&edition=fundamental","pubTime":"2025-03-21 20:23","pubTimestamp":1742559826,"startTime":"0","endTime":"0","summary":"Soligenix Inc reports results for the quarter ended December 31 - Earnings SummarySoligenix Inc SNGX.OQ reported a quarterly adjusted loss of $1.14 per share for the quarter ended December 31, higher ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL8N3Q40ZU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX"],"gpt_icon":0},{"id":"2521407754","title":"Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521407754","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521407754?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:30","pubTimestamp":1742556602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nTUA2DMC9X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2521072414","title":"Press Release: Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521072414","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521072414?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:30","pubTimestamp":1742556600,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., March 21, 2025 /PRNewswire/ -- Soligenix, Inc.  , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2024.Dr. Schaber continued, \"With approximately $7.8 million in cash at December 31, 2024, we are committed to disciplined resource allocation to achieve our strategic goals. While this cash balance provides operating runway through 2025, we continue to evaluate all strategic options, including partnership, merger and acquisition, government grants, and potential financing opportunities to advance our late-stage pipeline and the Company.\". with early-stage CTCL. To view this press release, please click here.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","MAB","BK4555","R","IDR","BK4022","BK4585","BK4139","BK4168","SNGX","BK4232","03160","TM","BK4588","BK4604"],"gpt_icon":0},{"id":"2519010978","title":"Soligenix Inc  expected to post a loss of 95 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2519010978","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519010978?lang=en_us&edition=fundamental","pubTime":"2025-03-14 21:12","pubTimestamp":1741957926,"startTime":"0","endTime":"0","summary":"Soligenix Inc  expected to post a loss of95cents a share - Earnings Preview Soligenix Inc SNGX.OQ SNGX.O is expected to show a rise in quarterly revenue when it reports  results on March 17 (estimated","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL8N3PX18F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX"],"gpt_icon":0},{"id":"2517086154","title":"HyBryte™ Treatment Studies Presented at Two Medical Conferences in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2517086154","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517086154?lang=en_us&edition=fundamental","pubTime":"2025-03-06 20:30","pubTimestamp":1741264200,"startTime":"0","endTime":"0","summary":"Two Presentations Highlight Data Demonstrating Hypericin Photodynamic Therapy Potential with a Preliminary Comparison to Current Therapy. Conference: USCLC Workshop \"Cutaneous Lymphomas in Special Populations\" March 6, Orlando, Florida. The official conference program can be found here.Presentation Title: Topical hypericin ointment photodynamic therapy for early stage mycosis fungoides/CTCL – a Phase 2 real world investigator-initiated study presented by Dr. Ellen Kim, Director, Penn Cutaneous Lymphoma Program, Vice Chair of Clinical Operations, Dermatology Department, and Professor of Dermatology at the Hospital of the University of Pennsylvania.presented by Dr. Neal Bhatia, Director of Clinical Dermatology at Therapeutics Clinical Research and chief medical editor at Practical Dermatology. The official conference program can be found here.These presentations incorporate the Company's findings in recentsupportive studies which have demonstrated the utility of longer treatment times, t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hybryte-treatment-studies-presented-two-123000102.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hybryte-treatment-studies-presented-two-123000102.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IDR","SNGX","BSA","BK4168"],"gpt_icon":0},{"id":"2514067427","title":"SNGX: Presentation Highlights HyBryte Potential in CTCL…","url":"https://stock-news.laohu8.com/highlight/detail?id=2514067427","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514067427?lang=en_us&edition=fundamental","pubTime":"2025-02-25 00:02","pubTimestamp":1740412920,"startTime":"0","endTime":"0","summary":"In January 2025, Dr. Neal Bhatia presented at two dermatology conferences on “Off-Label Uses of PDT” . Dr. Bhatia is the Director of Clinical Dermatology at Therapeutics Clinical Research, a member of Soligenix’s  scientific advisory board, and was a participating investigator in the Phase 3 HyBryte trial. During his presentation, Dr. Bhatia discussed the efficacy results from multiple studies of HyBryte along with results from studies examining Valchlor , also known as nitrogen mustard , which is indicated for the treatment of Stage IA and IB mycosis fungoides-type cutaneous T cell lymphoma . Valchlor was approved based in part on the results of a Phase 3 trial in which it was compared to a compounded 0.02% mechlorethamine ointment . The study was successful and showed that Valchlor was superior to the ointment .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sngx-presentation-highlights-hybryte-potential-160200810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4021","SNGX","NM"],"gpt_icon":0},{"id":"2510859400","title":"Soligenix Inc - on Feb 5, Repays and Terminates Loan Agreement With Pontifax Medison","url":"https://stock-news.laohu8.com/highlight/detail?id=2510859400","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510859400?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:33","pubTimestamp":1739190790,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nFWN3P10G6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2503524270","title":"Soligenix’s HyBryte shows efficacy in T-cell lymphoma trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2503524270","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503524270?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:35","pubTimestamp":1736858116,"startTime":"0","endTime":"0","summary":"Soligenix (SNGX) announced an interim update on the open-label, investigator-initiated study evaluating extended HyBryte – synthetic hypericin – tr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/soligenixs-hybryte-shows-efficacy-in-t-cell-lymphoma-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/soligenixs-hybryte-shows-efficacy-in-t-cell-lymphoma-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2503241045","title":"BRIEF-HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2503241045","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503241045?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:34","pubTimestamp":1736858043,"startTime":"0","endTime":"0","summary":"BRIEF-HyBryte Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell LymphomaJan 14 (Reuters) - Soligenix Inc SNGX.O:HYBRYTE EXPANDED TREATMENT CONTINUES TO DEMO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nFWN3OA0Q4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2503524929","title":"Hybryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2503524929","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503524929?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:30","pubTimestamp":1736857827,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nFWN3OA0Q4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2503655520","title":"EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2503655520","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503655520?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:15","pubTimestamp":1736856917,"startTime":"0","endTime":"0","summary":"On Tuesday, Soligenix Inc.  announced an interim update on the open-label, investigator-initiated study  evaluating extended HyBryte  treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma , a type of cancer that starts in the T-lymphocytes, a type of white blood cell that fights infection.Cutaneous T-cell lymphomais a groupof rare blood cancersthat affects the skin.Nine patients have been enrolled and treated with HyBryte over up to 54 weeks.Also Read: Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels. Patients have responded positively to HyBryte therapy, with over 70%  already achieving \"Treatment Success.\". Treatment Success is predefined in the study's protocol as a greater than or equal to 50% improvement in the cumulative mCAILS  score compared to the baseline.Three of the five Treatment Successes were achieved within the first 12 weeks of treatment, with two patients achieving a \"complete response\" by 18 weeks","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-soligenixs-cancer-candidate-shows-121517231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2503503280","title":"SNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL…","url":"https://stock-news.laohu8.com/highlight/detail?id=2503503280","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503503280?lang=en_us&edition=fundamental","pubTime":"2025-01-14 18:09","pubTimestamp":1736849340,"startTime":"0","endTime":"0","summary":"On January 14, 2025, Soligenix, Inc.  announced additional positive data from the open-label, investigator-initiated study  of HyBryte  for patients with cutaneous T cell lymphoma  for up to 12 months. During the study patients are treated twice a week and the protocol allows for the potential transition to a “real-world” setting with at-home use. The trial is being sponsored by Dr. Ellen Kim, Director, Penn Cutaneous Lymphoma Program, Vice Chair of Clinical Operations, Dermatology Department, and Professor of Dermatology at the Hospital of the University of Pennsylvania and is being funded by a $2.6 million Orphan Products Development Grant from the FDA.DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing rese","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sngx-additional-positive-outcomes-investigator-100900289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2491693787","title":"Soligenix Begins Patient Enrollment for Phase 3 Study of Drug Candidate for Cutaneous T-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2491693787","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491693787?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:05","pubTimestamp":1734354345,"startTime":"0","endTime":"0","summary":"Soligenix (SNGX) said Monday it has begun patient enrollment for its phase 3 study of its experimental therapy, HyBryte, to treat cutaneous T-cell lymphoma or CTCL.The company said the study builds on previous phase 3 results and additional supportive research.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2491660037","title":"Soligenix initiates confirmatory Phase 3 trial of HyBryte","url":"https://stock-news.laohu8.com/highlight/detail?id=2491660037","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491660037?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:35","pubTimestamp":1734352506,"startTime":"0","endTime":"0","summary":"Soligenix (SNGX) announced that it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte in the treatment of cutaneou...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/soligenix-initiates-confirmatory-phase-3-trial-of-hybryte?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/soligenix-initiates-confirmatory-phase-3-trial-of-hybryte?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SNGX"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SNGX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-21","symbol":"SNGX","fiscalQuarterEnding":"2024/12","expectedEps":-0.95,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742529600000,"reportTimeType":"pre","actualEps":-1.14},{"market":"US","date":"2024-11-08","symbol":"SNGX","fiscalQuarterEnding":"2024/09","expectedEps":-1.09,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731042000000,"reportTimeType":"pre","actualEps":-0.78},{"market":"US","date":"2024-08-09","symbol":"SNGX","fiscalQuarterEnding":"2024/06","expectedEps":-2.11,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"pre","actualEps":-1.31},{"market":"US","date":"2024-06-06","symbol":"SNGX","defaultRemindTime":1717680600000,"type":"split","dateTimestamp":1717646400000,"forFactor":16,"toFactor":1,"ratio":16},{"market":"US","date":"2024-05-10","symbol":"SNGX","fiscalQuarterEnding":"2024/03","expectedEps":-0.2,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715313600000,"reportTimeType":"pre","actualEps":-0.18}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SNGX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SNGX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SNGX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SNGX","date":"2025-04-28","current":-0.828355,"percent":0.749188,"low":-5.464746,"twenty":-3.349117,"median":-1.686663,"eighty":-0.778595,"high":-0.277411,"avg":-1.962758,"sd":1.247866,"marketCap":6847658},"quantilePoints":[{"date":"2020-05-01","current":-4.215765,"twenty":-3.71974,"median":-2.965739,"eighty":-2.106354,"marketCap":39440977},{"date":"2020-05-08","current":-4.491305,"twenty":-3.744873,"median":-2.965739,"eighty":-2.106354,"marketCap":42018818},{"date":"2020-05-15","current":-2.72763,"twenty":-3.745836,"median":-2.963367,"eighty":-2.106354,"marketCap":41725374},{"date":"2020-05-22","current":-3.648423,"twenty":-3.745836,"median":-2.957629,"eighty":-2.106354,"marketCap":55811010},{"date":"2020-05-29","current":-3.318327,"twenty":-3.745836,"median":-2.957629,"eighty":-2.106354,"marketCap":50761441},{"date":"2020-06-05","current":-3.683169,"twenty":-3.745836,"median":-2.957629,"eighty":-2.106354,"marketCap":56342543},{"date":"2020-06-12","current":-3.300954,"twenty":-3.747347,"median":-2.957629,"eighty":-2.106354,"marketCap":50495674},{"date":"2020-06-19","current":-3.075099,"twenty":-3.747347,"median":-2.957629,"eighty":-2.106354,"marketCap":47040707},{"date":"2020-06-26","current":-3.631049,"twenty":-3.744873,"median":-2.957629,"eighty":-2.106354,"marketCap":55545243},{"date":"2020-07-02","current":-3.405194,"twenty":-3.729793,"median":-2.957629,"eighty":-2.106354,"marketCap":52090276},{"date":"2020-07-10","current":-3.526808,"twenty":-3.712662,"median":-2.957629,"eighty":-2.106354,"marketCap":53950642},{"date":"2020-07-17","current":-4.183339,"twenty":-3.710161,"median":-2.957629,"eighty":-2.106354,"marketCap":63993787},{"date":"2020-07-24","current":-4.164923,"twenty":-3.710161,"median":-2.957629,"eighty":-2.106354,"marketCap":63712077},{"date":"2020-07-31","current":-4.202786,"twenty":-3.71974,"median":-2.957629,"eighty":-2.106354,"marketCap":64291278},{"date":"2020-08-07","current":-4.278512,"twenty":-3.73529,"median":-2.958383,"eighty":-2.106354,"marketCap":65449680},{"date":"2020-08-14","current":-3.798616,"twenty":-3.745836,"median":-2.963367,"eighty":-2.106354,"marketCap":60589987},{"date":"2020-08-21","current":-4.041878,"twenty":-3.787557,"median":-2.963367,"eighty":-2.106354,"marketCap":64470134},{"date":"2020-08-28","current":-3.686342,"twenty":-3.798616,"median":-2.963367,"eighty":-2.106354,"marketCap":58799151},{"date":"2020-09-04","current":-3.368231,"twenty":-3.793641,"median":-2.963367,"eighty":-2.106354,"marketCap":53725112},{"date":"2020-09-11","current":-3.555355,"twenty":-3.793641,"median":-2.963367,"eighty":-2.106354,"marketCap":56709840},{"date":"2020-09-18","current":-3.742479,"twenty":-3.793641,"median":-2.963367,"eighty":-2.106354,"marketCap":59694570},{"date":"2020-09-25","current":-3.181107,"twenty":-3.792424,"median":-2.965739,"eighty":-2.107674,"marketCap":50740384},{"date":"2020-10-02","current":-3.255957,"twenty":-3.792424,"median":-2.974005,"eighty":-2.107674,"marketCap":51934274},{"date":"2020-10-09","current":-3.349519,"twenty":-3.792424,"median":-2.993101,"eighty":-2.107674,"marketCap":53426639},{"date":"2020-10-16","current":-3.349519,"twenty":-3.792424,"median":-2.996669,"eighty":-2.107674,"marketCap":53426639},{"date":"2020-10-23","current":-3.405656,"twenty":-3.792424,"median":-3.016006,"eighty":-2.107674,"marketCap":54322058},{"date":"2020-10-30","current":-3.181107,"twenty":-3.792424,"median":-3.02874,"eighty":-2.107674,"marketCap":50740384},{"date":"2020-11-06","current":-3.068833,"twenty":-3.792424,"median":-3.03163,"eighty":-2.107674,"marketCap":48949546},{"date":"2020-11-13","current":-3.576924,"twenty":-3.792424,"median":-3.032343,"eighty":-2.107674,"marketCap":53725112},{"date":"2020-11-20","current":-4.371797,"twenty":-3.807236,"median":-3.032343,"eighty":-2.107674,"marketCap":65664026},{"date":"2020-11-27","current":-4.332053,"twenty":-3.808915,"median":-3.032343,"eighty":-2.107674,"marketCap":65067080},{"date":"2020-12-04","current":-4.967951,"twenty":-3.822057,"median":-3.032343,"eighty":-2.113513,"marketCap":74618212},{"date":"2020-12-11","current":-4.570515,"twenty":-3.833505,"median":-3.035911,"eighty":-2.115839,"marketCap":68648754},{"date":"2020-12-18","current":-5.325643,"twenty":-3.84402,"median":-3.041386,"eighty":-2.116451,"marketCap":79990722},{"date":"2020-12-24","current":-2.662821,"twenty":-3.835838,"median":-3.035911,"eighty":-2.116451,"marketCap":39995360},{"date":"2020-12-31","current":-2.543591,"twenty":-3.825781,"median":-3.032517,"eighty":-2.116451,"marketCap":38204524},{"date":"2021-01-08","current":-2.821796,"twenty":-3.820118,"median":-3.031986,"eighty":-2.116451,"marketCap":42383144},{"date":"2021-01-15","current":-2.997624,"twenty":-3.820118,"median":-3.02874,"eighty":-2.116451,"marketCap":45024063},{"date":"2021-01-22","current":-3.605533,"twenty":-3.820118,"median":-3.02874,"eighty":-2.116451,"marketCap":54154817},{"date":"2021-01-29","current":-3.249173,"twenty":-3.822057,"median":-3.02874,"eighty":-2.116451,"marketCap":48802306},{"date":"2021-02-05","current":-3.458797,"twenty":-3.822057,"median":-3.02874,"eighty":-2.116451,"marketCap":51950841},{"date":"2021-02-12","current":-4.485954,"twenty":-3.822137,"median":-3.02874,"eighty":-2.116451,"marketCap":67378666},{"date":"2021-02-19","current":-3.982857,"twenty":-3.833505,"median":-3.030551,"eighty":-2.116451,"marketCap":59822181},{"date":"2021-02-26","current":-3.458797,"twenty":-3.833505,"median":-3.03163,"eighty":-2.116451,"marketCap":51950841},{"date":"2021-03-05","current":-3.207248,"twenty":-3.835264,"median":-3.031519,"eighty":-2.11619,"marketCap":48172598},{"date":"2021-03-12","current":-3.75227,"twenty":-3.835264,"median":-3.03243,"eighty":-2.11619,"marketCap":56358791},{"date":"2021-03-19","current":-3.75227,"twenty":-3.83612,"median":-3.040991,"eighty":-2.11619,"marketCap":56358791},{"date":"2021-03-26","current":-3.270135,"twenty":-3.835838,"median":-3.042299,"eighty":-2.116451,"marketCap":49117159},{"date":"2021-04-01","current":-3.529516,"twenty":-3.826467,"median":-3.042299,"eighty":-2.116451,"marketCap":62431916},{"date":"2021-04-09","current":-3.41639,"twenty":-3.822157,"median":-3.042299,"eighty":-2.11619,"marketCap":60430892},{"date":"2021-04-16","current":-2.963888,"twenty":-3.822157,"median":-3.041843,"eighty":-2.11619,"marketCap":52426802},{"date":"2021-04-23","current":-3.212764,"twenty":-3.822057,"median":-3.040991,"eighty":-2.11619,"marketCap":56829052},{"date":"2021-04-30","current":-3.258014,"twenty":-3.822057,"median":-3.040991,"eighty":-2.11619,"marketCap":57629461},{"date":"2021-05-07","current":-2.896013,"twenty":-3.808915,"median":-3.033651,"eighty":-2.11619,"marketCap":51226187},{"date":"2021-05-14","current":-2.013634,"twenty":-3.807849,"median":-3.030979,"eighty":-2.11619,"marketCap":35618208},{"date":"2021-05-21","current":-3.342664,"twenty":-3.807849,"median":-3.034785,"eighty":-2.11619,"marketCap":41681899},{"date":"2021-05-28","current":-3.278382,"twenty":-3.807849,"median":-3.042299,"eighty":-2.11619,"marketCap":40880324},{"date":"2021-06-04","current":-3.471227,"twenty":-3.807849,"median":-3.047644,"eighty":-2.11619,"marketCap":43285047},{"date":"2021-06-11","current":-3.792638,"twenty":-3.808915,"median":-3.051016,"eighty":-2.11619,"marketCap":47292924},{"date":"2021-06-18","current":-3.599792,"twenty":-3.815158,"median":-3.058506,"eighty":-2.11619,"marketCap":44888198},{"date":"2021-06-25","current":-3.696215,"twenty":-3.815158,"median":-3.073824,"eighty":-2.11619,"marketCap":46090561},{"date":"2021-07-02","current":-3.342664,"twenty":-3.814599,"median":-3.085535,"eighty":-2.11619,"marketCap":41681899},{"date":"2021-07-09","current":-3.406946,"twenty":-3.820677,"median":-3.087545,"eighty":-2.11619,"marketCap":42483474},{"date":"2021-07-16","current":-3.149818,"twenty":-3.820677,"median":-3.091406,"eighty":-2.11619,"marketCap":39277173},{"date":"2021-07-23","current":-3.10032,"twenty":-3.820677,"median":-3.101159,"eighty":-2.11619,"marketCap":38659960},{"date":"2021-07-30","current":-3.063037,"twenty":-3.820677,"median":-3.120558,"eighty":-2.11619,"marketCap":38195046},{"date":"2021-08-06","current":-3.2141,"twenty":-3.820677,"median":-3.123123,"eighty":-2.11619,"marketCap":40078748},{"date":"2021-08-13","current":-3.271976,"twenty":-3.820677,"median":-3.12497,"eighty":-2.116451,"marketCap":37922108},{"date":"2021-08-20","current":-3.183049,"twenty":-3.820677,"median":-3.127219,"eighty":-2.128852,"marketCap":36891443},{"date":"2021-08-27","current":-3.529416,"twenty":-3.819297,"median":-3.140414,"eighty":-2.139444,"marketCap":40905829},{"date":"2021-09-03","current":-3.806233,"twenty":-3.819297,"median":-3.149818,"eighty":-2.140169,"marketCap":44114128},{"date":"2021-09-10","current":-4.013846,"twenty":-3.822057,"median":-3.152361,"eighty":-2.145333,"marketCap":46520354},{"date":"2021-09-17","current":-3.737029,"twenty":-3.822117,"median":-3.16435,"eighty":-2.145333,"marketCap":43312052},{"date":"2021-09-24","current":-3.546717,"twenty":-3.822117,"median":-3.180179,"eighty":-2.145333,"marketCap":41106347},{"date":"2021-10-01","current":-3.633222,"twenty":-3.822117,"median":-3.181533,"eighty":-2.145333,"marketCap":42108942},{"date":"2021-10-08","current":-3.59862,"twenty":-3.822117,"median":-3.189617,"eighty":-2.145333,"marketCap":41707904},{"date":"2021-10-15","current":-3.806233,"twenty":-3.822117,"median":-3.197852,"eighty":-2.150499,"marketCap":44114128},{"date":"2021-10-22","current":-3.494814,"twenty":-3.822117,"median":-3.211097,"eighty":-2.154035,"marketCap":40504791},{"date":"2021-10-29","current":-3.494814,"twenty":-3.822117,"median":-3.2141,"eighty":-2.161849,"marketCap":40504791},{"date":"2021-11-05","current":-3.42561,"twenty":-3.822117,"median":-3.220267,"eighty":-2.162699,"marketCap":39702715},{"date":"2021-11-12","current":-2.916544,"twenty":-3.822117,"median":-3.222002,"eighty":-2.170406,"marketCap":39044830},{"date":"2021-11-19","current":-2.741366,"twenty":-3.822117,"median":-3.218265,"eighty":-2.170406,"marketCap":36699653},{"date":"2021-11-26","current":-2.875872,"twenty":-3.822117,"median":-3.216049,"eighty":-2.170406,"marketCap":38500338},{"date":"2021-12-03","current":-2.562024,"twenty":-3.822117,"median":-3.2141,"eighty":-2.170406,"marketCap":34298742},{"date":"2021-12-10","current":-2.446092,"twenty":-3.822117,"median":-3.2141,"eighty":-2.170406,"marketCap":32746723},{"date":"2021-12-17","current":-2.394211,"twenty":-3.822117,"median":-3.211931,"eighty":-2.170406,"marketCap":32052174},{"date":"2021-12-23","current":-2.458582,"twenty":-3.822117,"median":-3.203637,"eighty":-2.170406,"marketCap":32913930},{"date":"2021-12-31","current":-2.114631,"twenty":-3.822117,"median":-3.191039,"eighty":-2.169084,"marketCap":28309324},{"date":"2022-01-07","current":-2.217909,"twenty":-3.822097,"median":-3.181959,"eighty":-2.166201,"marketCap":29691947},{"date":"2022-01-14","current":-2.069155,"twenty":-3.813481,"median":-3.181107,"eighty":-2.161849,"marketCap":27700521},{"date":"2022-01-21","current":-2.036489,"twenty":-3.810294,"median":-3.1662,"eighty":-2.161849,"marketCap":27263212},{"date":"2022-01-28","current":-1.97436,"twenty":-3.809605,"median":-3.158329,"eighty":-2.15359,"marketCap":26431467},{"date":"2022-02-04","current":-1.986209,"twenty":-3.809605,"median":-3.149818,"eighty":-2.148285,"marketCap":26590099},{"date":"2022-02-11","current":-2.014712,"twenty":-3.809605,"median":-3.144477,"eighty":-2.14007,"marketCap":26971673},{"date":"2022-02-18","current":-2.17772,"twenty":-3.809605,"median":-3.132783,"eighty":-2.139444,"marketCap":29153928},{"date":"2022-02-25","current":-2.306142,"twenty":-3.809605,"median":-3.129679,"eighty":-2.139444,"marketCap":30873154},{"date":"2022-03-04","current":-2.145054,"twenty":-3.809605,"median":-3.129679,"eighty":-2.138219,"marketCap":28716619},{"date":"2022-03-11","current":-2.312226,"twenty":-3.809605,"median":-3.124184,"eighty":-2.138219,"marketCap":30954613},{"date":"2022-03-18","current":-2.222556,"twenty":-3.806233,"median":-3.11997,"eighty":-2.138219,"marketCap":29754157},{"date":"2022-03-25","current":-2.309344,"twenty":-3.806233,"median":-3.105034,"eighty":-2.138219,"marketCap":30916027},{"date":"2022-04-01","current":-2.532554,"twenty":-3.806233,"median":-3.105034,"eighty":-2.139763,"marketCap":31786020},{"date":"2022-04-08","current":-2.529132,"twenty":-3.806233,"median":-3.105034,"eighty":-2.14463,"marketCap":31743066},{"date":"2022-04-14","current":-2.481219,"twenty":-3.806233,"median":-3.105034,"eighty":-2.150636,"marketCap":31141708},{"date":"2022-04-22","current":-2.102362,"twenty":-3.806233,"median":-3.105034,"eighty":-2.152006,"marketCap":26386692},{"date":"2022-04-29","current":-1.80975,"twenty":-3.806233,"median":-3.105034,"eighty":-2.14463,"marketCap":22714119},{"date":"2022-05-06","current":-1.772104,"twenty":-3.806233,"median":-3.105034,"eighty":-2.142794,"marketCap":22241624},{"date":"2022-05-13","current":-1.178605,"twenty":-3.806233,"median":-3.100739,"eighty":-2.140196,"marketCap":17133992},{"date":"2022-05-20","current":-1.543144,"twenty":-3.806233,"median":-3.091406,"eighty":-2.139444,"marketCap":22433476},{"date":"2022-05-27","current":-1.77383,"twenty":-3.806233,"median":-3.089475,"eighty":-2.129342,"marketCap":25787088},{"date":"2022-06-03","current":-1.514419,"twenty":-3.806233,"median":-3.087545,"eighty":-2.119815,"marketCap":22015888},{"date":"2022-06-10","current":-1.776792,"twenty":-3.806233,"median":-3.087545,"eighty":-2.115527,"marketCap":25830138},{"date":"2022-06-17","current":-1.687952,"twenty":-3.806233,"median":-3.087545,"eighty":-2.100887,"marketCap":24538630},{"date":"2022-06-24","current":-1.617473,"twenty":-3.806233,"median":-3.087545,"eighty":-2.092935,"marketCap":23514034},{"date":"2022-07-01","current":-1.719934,"twenty":-3.806233,"median":-3.087545,"eighty":-2.086976,"marketCap":25003573},{"date":"2022-07-08","current":-1.762281,"twenty":-3.806233,"median":-3.087545,"eighty":-2.078536,"marketCap":25619192},{"date":"2022-07-15","current":-2.025543,"twenty":-3.806233,"median":-3.087545,"eighty":-2.0727,"marketCap":29446357},{"date":"2022-07-22","current":-2.259783,"twenty":-3.806233,"median":-3.077014,"eighty":-2.0727,"marketCap":32851632},{"date":"2022-07-29","current":-2.592339,"twenty":-3.806233,"median":-3.070415,"eighty":-2.0727,"marketCap":37686173},{"date":"2022-08-05","current":-2.679994,"twenty":-3.806233,"median":-3.070415,"eighty":-2.0727,"marketCap":38960460},{"date":"2022-08-12","current":-2.539174,"twenty":-3.806233,"median":-3.068833,"eighty":-2.0727,"marketCap":38156702},{"date":"2022-08-19","current":-2.380834,"twenty":-3.793261,"median":-3.057725,"eighty":-2.0727,"marketCap":35777295},{"date":"2022-08-26","current":-2.280438,"twenty":-3.77381,"median":-3.037933,"eighty":-2.0727,"marketCap":34268616},{"date":"2022-09-02","current":-2.065302,"twenty":-3.75227,"median":-3.012696,"eighty":-2.072608,"marketCap":31035726},{"date":"2022-09-09","current":-1.986419,"twenty":-3.744873,"median":-2.99389,"eighty":-2.068643,"marketCap":29850333},{"date":"2022-09-16","current":-1.921878,"twenty":-3.736351,"median":-2.972351,"eighty":-2.06071,"marketCap":28880466},{"date":"2022-09-23","current":-1.455464,"twenty":-3.71974,"median":-2.963888,"eighty":-2.050413,"marketCap":21871566},{"date":"2022-09-30","current":-1.252663,"twenty":-3.703324,"median":-2.929273,"eighty":-2.049272,"marketCap":18824029},{"date":"2022-10-07","current":-1.641628,"twenty":-3.69525,"median":-2.907735,"eighty":-2.046565,"marketCap":24669091},{"date":"2022-10-14","current":-1.686663,"twenty":-3.686342,"median":-2.894033,"eighty":-2.042346,"marketCap":25345843},{"date":"2022-10-21","current":-1.804558,"twenty":-3.668494,"median":-2.865205,"eighty":-2.037717,"marketCap":27117466},{"date":"2022-10-28","current":-2.007933,"twenty":-3.667825,"median":-2.841668,"eighty":-2.029514,"marketCap":30173622},{"date":"2022-11-04","current":-1.893481,"twenty":-3.66653,"median":-2.8149,"eighty":-2.026959,"marketCap":28453728},{"date":"2022-11-11","current":-2.05165,"twenty":-3.663597,"median":-2.797124,"eighty":-2.021049,"marketCap":30259092},{"date":"2022-11-18","current":-1.905104,"twenty":-3.648917,"median":-2.778014,"eighty":-2.01711,"marketCap":28097730},{"date":"2022-11-25","current":-1.699939,"twenty":-3.641768,"median":-2.743928,"eighty":-2.014281,"marketCap":25071819},{"date":"2022-12-02","current":-1.64132,"twenty":-3.633222,"median":-2.735277,"eighty":-2.004814,"marketCap":24207273},{"date":"2022-12-09","current":-1.533755,"twenty":-3.633222,"median":-2.711283,"eighty":-1.996265,"marketCap":22620834},{"date":"2022-12-16","current":-1.846485,"twenty":-3.633222,"median":-2.682693,"eighty":-1.984215,"marketCap":27233184},{"date":"2022-12-23","current":-1.891329,"twenty":-3.633222,"median":-2.662821,"eighty":-1.97859,"marketCap":27894562},{"date":"2022-12-30","current":-1.32478,"twenty":-3.633222,"median":-2.64295,"eighty":-1.974296,"marketCap":19538728},{"date":"2023-01-06","current":-1.410357,"twenty":-3.630477,"median":-2.626074,"eighty":-1.970255,"marketCap":20800882},{"date":"2023-01-13","current":-1.377155,"twenty":-3.619207,"median":-2.596781,"eighty":-1.964148,"marketCap":20311194},{"date":"2023-01-20","current":-1.469416,"twenty":-3.619207,"median":-2.584653,"eighty":-1.961265,"marketCap":21671919},{"date":"2023-01-27","current":-1.409182,"twenty":-3.619207,"median":-2.562024,"eighty":-1.955717,"marketCap":20783547},{"date":"2023-02-03","current":-1.351886,"twenty":-3.615611,"median":-2.546439,"eighty":-1.950333,"marketCap":19938511},{"date":"2023-02-10","current":-1.047974,"twenty":-3.615611,"median":-2.539174,"eighty":-1.93629,"marketCap":15456214},{"date":"2023-02-17","current":-0.812914,"twenty":-3.615611,"median":-2.519549,"eighty":-1.920521,"marketCap":11989399},{"date":"2023-02-24","current":-0.744355,"twenty":-3.615611,"median":-2.50894,"eighty":-1.916691,"marketCap":10978245},{"date":"2023-03-03","current":-0.579814,"twenty":-3.615611,"median":-2.50315,"eighty":-1.905104,"marketCap":8551475},{"date":"2023-03-10","current":-0.628784,"twenty":-3.615611,"median":-2.498294,"eighty":-1.893481,"marketCap":9273728},{"date":"2023-03-17","current":-0.45249,"twenty":-3.615611,"median":-2.494874,"eighty":-1.873469,"marketCap":6673617},{"date":"2023-03-24","current":-0.360425,"twenty":-3.615611,"median":-2.490459,"eighty":-1.864593,"marketCap":5315782},{"date":"2023-03-31","current":-0.385889,"twenty":-3.614644,"median":-2.487664,"eighty":-1.852184,"marketCap":5691353},{"date":"2023-04-06","current":-0.368498,"twenty":-3.614644,"median":-2.487664,"eighty":-1.838884,"marketCap":5084661},{"date":"2023-04-14","current":-0.343373,"twenty":-3.615611,"median":-2.488267,"eighty":-1.81823,"marketCap":4737979},{"date":"2023-04-21","current":-0.311554,"twenty":-3.615611,"median":-2.488267,"eighty":-1.806924,"marketCap":4298921},{"date":"2023-04-28","current":-0.311554,"twenty":-3.615611,"median":-2.488267,"eighty":-1.796476,"marketCap":4298921},{"date":"2023-05-05","current":-0.486536,"twenty":-3.615611,"median":-2.488267,"eighty":-1.780665,"marketCap":6713384},{"date":"2023-05-12","current":-0.530952,"twenty":-3.615611,"median":-2.488267,"eighty":-1.774785,"marketCap":7326252},{"date":"2023-05-19","current":-0.450777,"twenty":-3.615611,"median":-2.488267,"eighty":-1.773356,"marketCap":4731101},{"date":"2023-05-26","current":-0.548639,"twenty":-3.615611,"median":-2.488267,"eighty":-1.762981,"marketCap":5758198},{"date":"2023-06-02","current":-0.556758,"twenty":-3.615611,"median":-2.488267,"eighty":-1.761231,"marketCap":5843414},{"date":"2023-06-09","current":-0.568435,"twenty":-3.615611,"median":-2.488267,"eighty":-1.758431,"marketCap":5965964},{"date":"2023-06-16","current":-0.553201,"twenty":-3.615611,"median":-2.488267,"eighty":-1.753075,"marketCap":5806081},{"date":"2023-06-23","current":-0.549104,"twenty":-3.616579,"median":-2.489363,"eighty":-1.755221,"marketCap":5763076},{"date":"2023-06-30","current":-0.549025,"twenty":-3.617546,"median":-2.490459,"eighty":-1.751843,"marketCap":5762256},{"date":"2023-07-07","current":-0.561243,"twenty":-3.617546,"median":-2.490459,"eighty":-1.719975,"marketCap":5890486},{"date":"2023-07-14","current":-0.534333,"twenty":-3.617546,"median":-2.490459,"eighty":-1.701031,"marketCap":5608055},{"date":"2023-07-21","current":-0.517398,"twenty":-3.617546,"median":-2.488267,"eighty":-1.696019,"marketCap":5430317},{"date":"2023-07-28","current":-0.487163,"twenty":-3.617546,"median":-2.48706,"eighty":-1.691433,"marketCap":5112988},{"date":"2023-08-04","current":-0.458552,"twenty":-3.617546,"median":-2.471478,"eighty":-1.68556,"marketCap":4812701},{"date":"2023-08-11","current":-0.492307,"twenty":-3.605533,"median":-2.464449,"eighty":-1.673383,"marketCap":5166973},{"date":"2023-08-18","current":-0.451047,"twenty":-3.604385,"median":-2.451581,"eighty":-1.658517,"marketCap":4733931},{"date":"2023-08-25","current":-0.474846,"twenty":-3.599792,"median":-2.429294,"eighty":-1.650503,"marketCap":4615829},{"date":"2023-09-01","current":-0.455119,"twenty":-3.59581,"median":-2.407007,"eighty":-1.641321,"marketCap":4424070},{"date":"2023-09-08","current":-0.515598,"twenty":-3.574766,"median":-2.401897,"eighty":-1.635487,"marketCap":5011970},{"date":"2023-09-15","current":-0.457243,"twenty":-3.566924,"median":-2.38362,"eighty":-1.627894,"marketCap":4444715},{"date":"2023-09-22","current":-0.50771,"twenty":-3.560315,"median":-2.374811,"eighty":-1.617598,"marketCap":4935296},{"date":"2023-09-29","current":-0.546143,"twenty":-3.551056,"median":-2.338167,"eighty":-1.605284,"marketCap":5308884},{"date":"2023-10-06","current":-0.576484,"twenty":-3.535509,"median":-2.330801,"eighty":-1.598066,"marketCap":5603822},{"date":"2023-10-13","current":-0.56637,"twenty":-3.529416,"median":-2.317858,"eighty":-1.582702,"marketCap":5505509},{"date":"2023-10-20","current":-0.529961,"twenty":-3.529416,"median":-2.309344,"eighty":-1.582674,"marketCap":5151583},{"date":"2023-10-27","current":-0.515296,"twenty":-3.529416,"median":-2.303676,"eighty":-1.573299,"marketCap":5009030},{"date":"2023-11-03","current":-0.488595,"twenty":-3.529416,"median":-2.295319,"eighty":-1.555321,"marketCap":4749485},{"date":"2023-11-10","current":-0.420732,"twenty":-3.529416,"median":-2.279706,"eighty":-1.52544,"marketCap":4089807},{"date":"2023-11-17","current":-0.49227,"twenty":-3.529416,"median":-2.266533,"eighty":-1.497359,"marketCap":3974781},{"date":"2023-11-24","current":-0.519915,"twenty":-3.529416,"median":-2.255719,"eighty":-1.484111,"marketCap":4197997},{"date":"2023-12-01","current":-1.259878,"twenty":-3.529416,"median":-2.246954,"eighty":-1.471408,"marketCap":10172748},{"date":"2023-12-08","current":-0.944716,"twenty":-3.529416,"median":-2.243626,"eighty":-1.458806,"marketCap":7628004},{"date":"2023-12-15","current":-0.760271,"twenty":-3.529416,"median":-2.242091,"eighty":-1.44978,"marketCap":6138727},{"date":"2023-12-22","current":-0.781479,"twenty":-3.529416,"median":-2.242091,"eighty":-1.42203,"marketCap":6309968},{"date":"2023-12-29","current":-0.878907,"twenty":-3.529416,"median":-2.242858,"eighty":-1.409887,"marketCap":7096639},{"date":"2024-01-05","current":-1.166178,"twenty":-3.529416,"median":-2.243626,"eighty":-1.402478,"marketCap":9416175},{"date":"2024-01-12","current":-1.113479,"twenty":-3.529416,"median":-2.241771,"eighty":-1.377273,"marketCap":8990667},{"date":"2024-01-19","current":-0.798188,"twenty":-3.529416,"median":-2.240902,"eighty":-1.367144,"marketCap":6444885},{"date":"2024-01-26","current":-0.76477,"twenty":-3.529416,"median":-2.232464,"eighty":-1.350711,"marketCap":6175051},{"date":"2024-02-02","current":-0.861041,"twenty":-3.529416,"median":-2.232464,"eighty":-1.323591,"marketCap":6952381},{"date":"2024-02-09","current":-0.832892,"twenty":-3.529416,"median":-2.232464,"eighty":-1.284479,"marketCap":6725098},{"date":"2024-02-16","current":-0.935719,"twenty":-3.529416,"median":-2.232464,"eighty":-1.19338,"marketCap":7555357},{"date":"2024-02-23","current":-0.96014,"twenty":-3.529416,"median":-2.232464,"eighty":-1.170061,"marketCap":7752543},{"date":"2024-03-01","current":-0.937004,"twenty":-3.529416,"median":-2.232314,"eighty":-1.094071,"marketCap":7565735},{"date":"2024-03-08","current":-1.015409,"twenty":-3.529416,"median":-2.232314,"eighty":-1.04266,"marketCap":8198808},{"date":"2024-03-15","current":-0.818497,"twenty":-3.529416,"median":-2.232314,"eighty":-0.985743,"marketCap":6608861},{"date":"2024-03-22","current":-1.096879,"twenty":-3.529416,"median":-2.231918,"eighty":-0.985743,"marketCap":6735639},{"date":"2024-03-28","current":-1.040493,"twenty":-3.529416,"median":-2.231918,"eighty":-0.985743,"marketCap":6389385},{"date":"2024-04-05","current":-0.805692,"twenty":-3.529416,"median":-2.232163,"eighty":-0.951971,"marketCap":4947537},{"date":"2024-04-12","current":-0.666183,"twenty":-3.529416,"median":-2.232163,"eighty":-0.937467,"marketCap":4090848},{"date":"2024-04-19","current":-0.746049,"twenty":-3.529416,"median":-2.232163,"eighty":-0.925458,"marketCap":4581287},{"date":"2024-04-26","current":-0.990316,"twenty":-3.529416,"median":-2.231918,"eighty":-0.92158,"marketCap":6081264},{"date":"2024-05-03","current":-0.938133,"twenty":-3.529416,"median":-2.231918,"eighty":-0.914511,"marketCap":5760823},{"date":"2024-05-10","current":-0.941612,"twenty":-3.529416,"median":-2.231918,"eighty":-0.914511,"marketCap":5782185},{"date":"2024-05-17","current":-0.792348,"twenty":-3.529416,"median":-2.231918,"eighty":-0.90316,"marketCap":5554316},{"date":"2024-05-24","current":-0.729366,"twenty":-3.529416,"median":-2.231918,"eighty":-0.885025,"marketCap":5112819},{"date":"2024-05-31","current":-0.711081,"twenty":-3.529416,"median":-2.231918,"eighty":-0.868111,"marketCap":4984642},{"date":"2024-06-07","current":-0.584609,"twenty":-3.529416,"median":-2.231918,"eighty":-0.841478,"marketCap":4098079},{"date":"2024-06-14","current":-0.584609,"twenty":-3.529416,"median":-2.232163,"eighty":-0.825714,"marketCap":4098079},{"date":"2024-06-21","current":-0.5184,"twenty":-3.529416,"median":-2.232314,"eighty":-0.813414,"marketCap":3633959},{"date":"2024-06-28","current":-0.373304,"twenty":-3.529416,"median":-2.233626,"eighty":-0.808757,"marketCap":2616845},{"date":"2024-07-05","current":-0.318365,"twenty":-3.529416,"median":-2.233626,"eighty":-0.804561,"marketCap":2231725},{"date":"2024-07-12","current":-1.077653,"twenty":-3.529416,"median":-2.233626,"eighty":-0.801249,"marketCap":7554290},{"date":"2024-07-15","current":-1.046662,"twenty":-3.529416,"median":-2.233626,"eighty":-0.801249,"marketCap":7337043},{"date":"2024-08-02","current":-0.618418,"twenty":-3.535509,"median":-2.215749,"eighty":-0.797123,"marketCap":4335076},{"date":"2024-08-09","current":-0.442331,"twenty":-3.535509,"median":-2.205592,"eighty":-0.792348,"marketCap":3100715},{"date":"2024-08-16","current":-1.081532,"twenty":-3.535509,"median":-2.189844,"eighty":-0.792348,"marketCap":7616606},{"date":"2024-08-23","current":-1.372962,"twenty":-3.535509,"median":-2.17772,"eighty":-0.792348,"marketCap":9668985},{"date":"2024-08-30","current":-1.058865,"twenty":-3.535509,"median":-2.174327,"eighty":-0.792348,"marketCap":7456976},{"date":"2024-09-06","current":-1.343819,"twenty":-3.535509,"median":-2.166303,"eighty":-0.792348,"marketCap":9463747},{"date":"2024-09-13","current":-1.110675,"twenty":-3.535509,"median":-2.161246,"eighty":-0.792348,"marketCap":7821844},{"date":"2024-09-20","current":-1.240199,"twenty":-3.535509,"median":-2.156951,"eighty":-0.792348,"marketCap":8734012},{"date":"2024-09-27","current":-1.246676,"twenty":-3.535509,"median":-2.145374,"eighty":-0.792348,"marketCap":8779620},{"date":"2024-10-04","current":-1.279057,"twenty":-3.535509,"median":-2.13956,"eighty":-0.792348,"marketCap":9007662},{"date":"2024-10-11","current":-1.292009,"twenty":-3.535509,"median":-2.13101,"eighty":-0.792348,"marketCap":9098879},{"date":"2024-10-18","current":-1.175437,"twenty":-3.535509,"median":-2.12822,"eighty":-0.792348,"marketCap":8277928},{"date":"2024-10-25","current":-1.20458,"twenty":-3.535509,"median":-2.123577,"eighty":-0.792348,"marketCap":8483166},{"date":"2024-10-31","current":-1.207818,"twenty":-3.535509,"median":-2.107658,"eighty":-0.792348,"marketCap":8505970},{"date":"2024-11-08","current":-1.123627,"twenty":-3.535509,"median":-2.074279,"eighty":-0.792348,"marketCap":7913060},{"date":"2024-11-15","current":-1.300862,"twenty":-3.535509,"median":-2.067722,"eighty":-0.792348,"marketCap":9234956},{"date":"2024-11-22","current":-1.187744,"twenty":-3.535509,"median":-2.067722,"eighty":-0.792348,"marketCap":8431916},{"date":"2024-11-29","current":-1.184209,"twenty":-3.535509,"median":-2.049939,"eighty":-0.792348,"marketCap":8406821},{"date":"2024-12-06","current":-1.131184,"twenty":-3.535509,"median":-2.033927,"eighty":-0.792348,"marketCap":8030396},{"date":"2024-12-13","current":-1.170069,"twenty":-3.535509,"median":-2.017112,"eighty":-0.792348,"marketCap":8306441},{"date":"2024-12-20","current":-1.088765,"twenty":-3.535509,"median":-2.001581,"eighty":-0.792348,"marketCap":7729256},{"date":"2024-12-27","current":-1.021601,"twenty":-3.535509,"median":-1.986209,"eighty":-0.792348,"marketCap":7252452},{"date":"2025-01-03","current":-1.039276,"twenty":-3.535509,"median":-1.976601,"eighty":-0.792348,"marketCap":7377927},{"date":"2025-01-10","current":-1.155929,"twenty":-3.529416,"median":-1.97197,"eighty":-0.792348,"marketCap":8206061},{"date":"2025-01-17","current":-0.802434,"twenty":-3.523734,"median":-1.964077,"eighty":-0.792348,"marketCap":5696562},{"date":"2025-01-24","current":-0.887273,"twenty":-3.508918,"median":-1.953718,"eighty":-0.792348,"marketCap":6298842},{"date":"2025-01-31","current":-0.816574,"twenty":-3.487384,"median":-1.94499,"eighty":-0.792348,"marketCap":5796942},{"date":"2025-02-07","current":-0.830713,"twenty":-3.464081,"median":-1.928314,"eighty":-0.792348,"marketCap":5897322},{"date":"2025-02-14","current":-0.869598,"twenty":-3.460004,"median":-1.914564,"eighty":-0.792348,"marketCap":6173367},{"date":"2025-02-21","current":-0.862528,"twenty":-3.449367,"median":-1.905104,"eighty":-0.792348,"marketCap":6123177},{"date":"2025-02-28","current":-0.795364,"twenty":-3.435067,"median":-1.886817,"eighty":-0.792348,"marketCap":5646372},{"date":"2025-03-07","current":-0.823644,"twenty":-3.423562,"median":-1.846485,"eighty":-0.790373,"marketCap":5847132},{"date":"2025-03-14","current":-0.813039,"twenty":-3.41639,"median":-1.80975,"eighty":-0.790373,"marketCap":5771847},{"date":"2025-03-21","current":-0.841318,"twenty":-3.407348,"median":-1.782714,"eighty":-0.790373,"marketCap":5972607},{"date":"2025-03-28","current":-0.866528,"twenty":-3.405471,"median":-1.77383,"eighty":-0.790373,"marketCap":7163218},{"date":"2025-04-04","current":-0.794114,"twenty":-3.378355,"median":-1.754307,"eighty":-0.790373,"marketCap":6564600},{"date":"2025-04-11","current":-0.72147,"twenty":-3.370724,"median":-1.718749,"eighty":-0.782944,"marketCap":5964089},{"date":"2025-04-17","current":-0.786365,"twenty":-3.368231,"median":-1.700232,"eighty":-0.779049,"marketCap":6500542},{"date":"2025-04-25","current":-0.822629,"twenty":-3.349519,"median":-1.687952,"eighty":-0.778595,"marketCap":6800324},{"date":"2025-04-28","current":-0.828355,"twenty":-3.349117,"median":-1.686663,"eighty":-0.778595,"marketCap":6847658}],"updateTime":1745920147339}}}